netFormulary
 Report : A-Z HCD items in Formulary 24/01/2021 23:53:33
[Back]
 
Section Status CCG Name
01.05.03 Formulary CCG Adalimumab 
13.05.03 Restricted Use CCG Adalimumab Humira®
02.12 Formulary CCG Alirocumab Praluent®
13.05.02 Formulary CCG Apremilast Otezla®
09.01.04 Formulary CCG Avatrombopag Doptelet®
04.12 Formulary CCG Botulinum neurotoxin Type A Xeomin®
10.01.03 Restricted Use CCG Brodalumab Kyntheum®
08.03.04.02 Formulary CCG Degarelix Firmagon®
13.05.03 Formulary CCG Dimethyl fumerate Skilarence®
13.05.03 Formulary CCG Dupilumab Dupixent®
09.01.04 Formulary CCG Eltrombopag  Revolade®
02.12 Formulary CCG Evolocumab Repatha®
06.01.06 Formulary CCG Flash glucose monitoring system FreeStyle Libre®
04.07.04.02 Formulary CCG Fremanezumab 
01.05.03 Formulary CCG Golimumab Simponi®
10.01.03 Restricted Use CCG Golimumab Simponi®
13.05.03 Formulary CCG Guselkumab Tremfya®
01.05.03 Formulary CCG Infliximab 
13.05.03 Restricted Use CCG Ixekizumab Taltz®
09.05.02.02 Formulary CCG Lanthanum Fosrenol ®
09.01.04 Formulary CCG Lusutrombopag Mulpleo®
03.04.02 Restricted Use CCG Omalizumab 
07.04.03 Formulary CCG Pentosan polysulfate sodium Elmiron®
13.05.03 Formulary CCG Risankizumab Skyrizi®
09.01.04 Formulary CCG Romiplostim Nplate®
09.05.02.02 Formulary CCG Sevelamer Carbonate tablets
13.05.03 Formulary CCG Tildrakizumab Ilumetri®
01.05.03 Formulary CCG Tofacitinib Xeljanz®
10.01.03 Formulary CCG Tofacitinib  Xeljanz ®
06.05.02 Restricted Use CCG Tolvaptan Jinarc®
01.05.03 Formulary CCG Ustekinumab Stelara®
13.05.03 Formulary CCG Ustekinumab 
01.05.03 Formulary CCG Vedolizumab Entyvio®
South Staffordshire Joint Formulary